Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

BioNTech CEO says vaccine upgrade on the cards, ready to move quickly

Stock MarketsDec 03, 2021 10:27AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A general view of the BioNTech building where the production of the coronavirus disease (COVID-19) vaccine has started in Marburg, Germany, November 18, 2021. REUTERS/Fabian Bimmer

By Ludwig Burger

FRANKFURT (Reuters) -BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur Sahin told the Reuters Next conference on Friday.

Sahin said people should continue to seek the established shot, developed with Pfizer (NYSE:PFE), as it very likely continues to protect against severe disease.

"I believe in principle at a certain timepoint we will need a new vaccine against this new variant. The question is how urgent it needs to be available," Sahin said.

He reiterated that a product relaunch could be achieved within about 100 days and said a redesign is already under way. But any confirmation of the existing shot's protection against severe disease could buy developers time for a more measured approach.

If third booster shots still prevent disease at an 85-90% rate "we would have more time to adapt a vaccine", he said.

Germany's BioNTech and Pfizer together produced one of the first vaccines against COVID-19, with well over 2 billion doses already given to protect people around the world.

There are concerns that the vaccines might not work as well against the Omicron variant which emerged last month.

Sahin reaffirmed his view, stated in a Reuters interview on Tuesday, that the new variant might infect vaccinated people but would likely prevent the need for hospital care.

"We expect that this new variant will evolve as an antibody escape variant. That means this variant might be able to infect vaccinated," Sahin said.

"We anticipate that infected people who have been vaccinated will still be protected against severe disease," Sahin added.

The BioNTech CEO, whose work until the emergence of the COVID-19 coronavirus in 2020 was focused on cancer, said the new variant had emerged sooner than he had anticipated.

"This highly mutant virus came earlier than I had expected. I had expected sometime next year and it's already with us."

Sahin also said that mutations in the virus meant it was more likely that annual vaccinations would be the norm, as is the case with seasonal flu.

Much remains unknown about Omicron, which was first detected in southern Africa last month and has been spotted in at least two dozen countries. It emerged just as parts of Europe were already grappling with a wave of Delta variant infections.

Asked how infectious the Omicron variant might be, Ozlem Tureci, BioNTech's chief medical officer and its co-founder said the next days or weeks would show.

BioNTech has been criticized for a slow rollout of vaccine deliveries in low-income countries. CEO Sahin said that a planned vaccine production network in Africa would eventually be transferred into local ownership and control.

"Our most important concern is to ensure that the quality is established. How this could be guaranteed when we transfer our technology, and when we transfer also the ownership, is something that we are discussing at the moment," he added.

But vaccine patents should not be waived, as U.S. President Joe Biden has suggested, because any knowledge transfer would require BioNTech's hands-on involvement.

Even the most experienced manufacturing contractors needed one-site supervision from BioNTech staff to produce consistent quality, Sahin said.

"It's not that we want to be involved, we have to be involved.

"I'm not against patent waivers," he added. "I'm seeking solutions."

To watch the Reuters Next conference please register here https://reutersevents.com/events/next

BioNTech CEO says vaccine upgrade on the cards, ready to move quickly
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email